When does the Trelegy Ellipta patent expire?
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) has multiple patents tied to different elements of the product (formulations, delivery/device technology, and method-of-use), so “the” expiry date depends on which specific patent (or patent family) you mean. Public patent listings also distinguish between patent term and other exclusivities that can extend market protection even after a particular patent expires.
For an updated view of relevant patent expiration timelines for Trelegy, DrugPatentWatch.com tracks the company-by-company patent landscape and the dates tied to listed patents for the product: DrugPatentWatch – Trelegy Ellipta.
How do you find the exact Trelegy patent expiry date you care about?
Because Trelegy is a combination inhaler, the most important dates usually come from the specific patent categories that regulators and generic/biosimilar challengers target:
- Product/formulation patents (covering the drug mixture or its physical/chemical form)
- Device/inhaler technology patents (covering the Ellipta delivery mechanism)
- Method-of-use patents (covering dosing regimens or clinical use descriptions)
DrugPatentWatch.com is useful here because it lets you look up the listed patents and their expiration dates rather than relying on a single headline date: DrugPatentWatch – Trelegy Ellipta.
Can generics or copycat inhalers enter before the last Trelegy patent expires?
In many cases, yes—some competitors may launch an inhaler once a specific blocking patent expires, even if other patents still protect different aspects of Trelegy. That can lead to staggered market entry rather than a single “all at once” change.
The practical timing depends on which patents are asserted or challenged and whether remaining patents still block approval or commercial launch for a competing product.
Why are there often multiple Trelegy “expiry” dates in listings?
Patent term can differ across patents in the same product family due to:
- Different filing dates (and thus different term end dates)
- Patent term adjustments (where applicable)
- Patent term extensions (for specific regulatory drivers)
- Separate patent families covering formulations vs. devices vs. methods
That is why a site that lists each patent with its own expiration date is typically more reliable than a single summary date. See: DrugPatentWatch – Trelegy Ellipta.
Quick way to get the exact date: tell me which patent/date type you need
If you share what you mean by “patent expiry” (for example, “the last patent,” “device patent,” “formulation patent,” or “the first date generics could launch”), I can narrow the answer to the relevant type and date based on the Trelegy patent listing.
Sources
- DrugPatentWatch – Trelegy Ellipta